Zacks: Analysts expect Check-Cap Ltd. (NASDAQ:CHEK) reports earnings of -$0.06 per share

Wall Street analysts expect Check-Cap Ltd. (NASDAQ:CHEKGet a rating) will show ($0.06) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have released earnings estimates for Check-Cap. The highest EPS estimate is ($0.05) and the lowest is ($0.07). Check-Cap reported earnings per share of ($0.05) in the same quarter last year, suggesting a negative 20% year-over-year growth rate. The company is expected to announce its next earnings report on Monday, January 1.

According to Zacks, analysts expect Check-Cap to report annual earnings of ($0.25) per share for the current fiscal year, with EPS estimates ranging from ($0.28) to ($0. .21). For the next fiscal year, analysts expect the company to post earnings of ($0.25) per share. Zacks’ earnings per share calculations are an average average based on a survey of sell-side analysts who follow Check-Cap.

Check Cap (NASDAQ:CHEKGet a rating) last released its quarterly results on Thursday, April 7. The medical research company reported ($0.06) earnings per share (EPS) for the quarter.

CHEK has been the subject of several recent analyst reports. Zacks Investment Research downgraded Check-Cap shares from a “buy” rating to a “hold” rating in a research note on Thursday. Dawson James upgraded Check-Cap shares from a “neutral” rating to a “buy” rating in a Monday, Feb. 7 research report.

CHECK traded down $0.02 during Monday’s trading, hitting $0.36. 418,496 shares of the stock have been traded, compared to its average volume of 1,115,484. The stock has a market capitalization of $34.60 million, a PE ratio of -1.70 and a beta of 0 ,20. Check-Cap has a 12-month low of $0.34 and a 12-month high of $1.91. The stock’s 50-day moving average is $0.41 and its 200-day moving average is $0.63.

Several hedge funds have recently bought and sold shares of the stock. Millennium Management LLC purchased a new stake in Check-Cap in the fourth quarter worth approximately $44,000. Two Sigma Securities LLC bought a new equity stake in Check-Cap in Q3 for $44,000. UBS Group AG increased its position in Check-Cap by 5,112.4% during the third quarter. UBS Group AG now owns 52,124 shares of the medical research company worth $46,000 after purchasing an additional 51,124 shares during the period. Goldman Sachs Group Inc. increased its position in Check-Cap by 784.5% during the third quarter. Goldman Sachs Group Inc. now owns 89,329 shares of the medical research company valued at $78,000 after acquiring an additional 79,230 shares last quarter. Finally, GSA Capital Partners LLP acquired a new stake in Check-Cap during the fourth quarter at a value of $206,000. 4.87% of the shares are held by hedge funds and other institutional investors.

Check Cap Company Profile (Get a rating)

Check-Cap Ltd., a clinical-stage medical diagnostics company, is engaged in the development of capsule-based screening technology that uses ultra-low dose x-rays to scan the inner lining of the colon at the search for precancerous polyps and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for the detection of suspicious polyps; C-Scan Track, a disposable system attached to the patient’s back by biocompatible adhesive skin patches; and C-Scan View software, a client/server application that allows downloading of procedure data from the C-Scan Track, data analysis and report generation.

Featured Articles

Get a Free Copy of Zacks Research Report on Check-Cap (CHEK)

For more information on Zacks Investment Research’s research offerings, visit

Get news and reviews for Check-Cap Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Check-Cap and related companies with’s free daily email newsletter.